PE20020842A1 - Antagonistas de receptores de aminoacidos excitadores - Google Patents

Antagonistas de receptores de aminoacidos excitadores

Info

Publication number
PE20020842A1
PE20020842A1 PE2002000004A PE2002000004A PE20020842A1 PE 20020842 A1 PE20020842 A1 PE 20020842A1 PE 2002000004 A PE2002000004 A PE 2002000004A PE 2002000004 A PE2002000004 A PE 2002000004A PE 20020842 A1 PE20020842 A1 PE 20020842A1
Authority
PE
Peru
Prior art keywords
antagonists
amino acid
acid receptors
tetrazole
alkyl
Prior art date
Application number
PE2002000004A
Other languages
English (en)
Inventor
Macklin Brian Arnold
Thomas John Bleich
Ana M Castano Mansanet
Esteban Dominguez-Manzanares
Ana Maria Escribano
Perez Jose Antonio Martinez
Ana Isabel Mateo Herranz
Paul Leslie Ornstein
Mark Alan Winter
Scott Allan Way
Andrew Michael Ratz
Michael Wilson Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20020842A1 publication Critical patent/PE20020842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE Z ES S, O; R1 ES H, CN, (C1-C4)ALQUIL-CO2H, TETRAZOL; R2 ES H, HALO, ARILO, ARILO SUSTITUIDO, CO2H, TETRAZOL, NHR3, ENTRE OTROS; R3 ES H, ALQUILO C1-C4, ALQUILARILO C1-C4, ENTRE OTROS; W, X, Y SON H, HALO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS. UN COMPUESTO PREFERIDO ES 2-ETIL-BUTIL(3S,4aR, 6S,8aR) 6-[3-CLORO-2-(1(2)H-TETRAZOL-5-IL)-FENOXI]-1,2,3,4,4a,5,6,7,8,8a-DECAHIDROISOQUINOLINA-3-CARBOXILATO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS DE FORMULA I SON ANTAGONISTAS DE RECEPTORES DE AMINOACIDOS EXCITADORES Y SON UTILES PARA EL TRATAMIENTO DE MULTIPLES TRASTORNOS NEUROLOGICOS, ENFERMEDADES NEURODEGENARATIVAS
PE2002000004A 2001-01-05 2002-01-04 Antagonistas de receptores de aminoacidos excitadores PE20020842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500004 2001-01-05

Publications (1)

Publication Number Publication Date
PE20020842A1 true PE20020842A1 (es) 2002-09-21

Family

ID=8183456

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000004A PE20020842A1 (es) 2001-01-05 2002-01-04 Antagonistas de receptores de aminoacidos excitadores

Country Status (16)

Country Link
EP (2) EP1368032B1 (es)
JP (2) JP4132049B2 (es)
CN (1) CN100548299C (es)
AR (1) AR035219A1 (es)
AT (1) ATE397931T1 (es)
AU (1) AU2001298028B8 (es)
BR (1) BR0116724A (es)
CA (1) CA2432464C (es)
CY (1) CY1108259T1 (es)
DE (1) DE60134427D1 (es)
DK (1) DK1368032T3 (es)
ES (1) ES2306690T3 (es)
MX (1) MXPA03005982A (es)
PE (1) PE20020842A1 (es)
PT (1) PT1368032E (es)
WO (1) WO2003024453A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091243A1 (en) 2002-04-26 2003-11-06 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
CN116332807A (zh) * 2023-03-24 2023-06-27 安徽秀朗新材料科技有限公司 一种3-（三氟甲基磺酰基）-2-萘甲酸甲酯的生产工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5446051A (en) * 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CN1259126A (zh) * 1997-04-07 2000-07-05 伊莱利利公司 药物
DK1200073T3 (da) * 1999-07-06 2007-05-07 Lilly Co Eli Selektive iGluR5-receptorantagonister til behandling af migræne
AU2574801A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists

Also Published As

Publication number Publication date
ATE397931T1 (de) 2008-07-15
CN100548299C (zh) 2009-10-14
WO2003024453A1 (en) 2003-03-27
EP1368032B1 (en) 2008-06-11
ES2306690T3 (es) 2008-11-16
CA2432464A1 (en) 2003-03-27
EP1368032A1 (en) 2003-12-10
EP2166003A1 (en) 2010-03-24
CN1856308A (zh) 2006-11-01
PT1368032E (pt) 2008-09-04
JP2008179650A (ja) 2008-08-07
MXPA03005982A (es) 2003-09-10
AU2001298028B8 (en) 2006-08-10
JP4132049B2 (ja) 2008-08-13
CY1108259T1 (el) 2014-02-12
DK1368032T3 (da) 2008-09-29
BR0116724A (pt) 2004-01-27
AR035219A1 (es) 2004-05-05
AU2001298028B2 (en) 2006-07-13
JP2004522804A (ja) 2004-07-29
CA2432464C (en) 2011-07-19
DE60134427D1 (de) 2008-07-24

Similar Documents

Publication Publication Date Title
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
CY1116082T1 (el) Μεθοδος παρασκευης ενωσεων βενζαζεπινης ή αλατων τους
EA200400054A1 (ru) Замещенные нафтилиндольные производные в качестве ингибиторов ингибитора активатора плазминогена типа 1 (pai-1)
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
BG104740A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists
PE20010299A1 (es) DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5
IS5497A (is) Bífenýlamidínafleiður
YU26499A (sh) Derivati diaza-spiro/3,5/nonana
PE20050393A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion
NO20020523L (no) Nye 2-dekarboksy-2-fosfinikoprostaglandin F-analoger
PE20020842A1 (es) Antagonistas de receptores de aminoacidos excitadores
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
PE20040605A1 (es) Nuevas diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenesas
PL377478A1 (pl) Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
HRP20041208A2 (en) Pyrrolidine derivatives as oxytocin antagonists
ES2069345T3 (es) Analogos heterociclicos de amida-prostaglandina 7-oxabiciclo-heptil-sustituidos utiles en el tratamiento de enfermedades tromboticas y vasoespasticas.
PA8525601A1 (es) Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
HUP0003856A2 (hu) 6-Pirrolidin-2-ilpirindin-származékok, eljárás előállításukra és gyógyászati alkalmazásuk
HUP0202293A2 (hu) Új N-benzilpiperazin vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
PE20030758A1 (es) 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion

Legal Events

Date Code Title Description
FD Application declared void or lapsed